Standard Versus Intensive Infliximab Induction in Acute Severe Ulcerative Colitis
Document Type
Conference Proceeding - Restricted Access
Publication Date
5-9-2025
Abstract
Infliximab (IFX), an anti-TNF agent, has been FDA-approved for the treatment of ulcerative colitis (UC) for nearly 20 years. The 2020 American Gastroenterologist Association Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis recommend IFX for the treatment of hospitalized adults with 72-hour intravenous (IV) corticosteroid-refractory acute severe ulcerative colitis (ASUC). IFX treatment begins with an induction phase and is followed by a maintenance phase. Standard IFX induction involves receipt of 5 mg/kg IV at 0, 2, and 6 weeks. In recent years, intensive IFX induction regimens have been used in the hopes of prolonging time to colectomy by accounting for hypoalbuminemia and accelerated consumption and fecal wasting of IFX in adults with ASUC. However, it is unclear if intensive induction regimens truly prolong time to colectomy.
Recommended Citation
Sannah R, Milanowski K, Watson A, Ice L. Standard versus intensive infliximab induction in acute severe ulcerative colitis. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.
Comments
2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1791